It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s highly anticipated next-generation obesity drug,...
Nvidia reports earnings this week with expectations still firmly elevated. Consensus continues to model strong revenue growth, healthy profitability,...